CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
etanerceptdrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Moderate to severe active rheumatoid arthritis
  • ✓Age 17 years or older
  • ✓Inadequate response to prior DMARDs
  • ✓Treating physician decision to prescribe Enbrel
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00195338
NCT00195338N/ACompleted
CompareCT.gov

A Post-Marketing Surveillance Looking At Safety And Adherence To Treatment Of Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg

Pfizer·observational·Posted Sep 19, 2005·Updated Jan 23, 2012

In Brief

An observational study evaluating etanercept for Rheumatoid Arthritis. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of the study is to determine the long term safety of Enbrel in adults with active rheumatoid arthritis in Luxemburg. This is a post-marketing surveillance study in rheumatology practice patients. All patients initiated with Enbrel will be observed from the start of the study in Feb 2003 for a period of at least 5 years.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesLuxembourg
CollaboratorsInnovex, Inc

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 19, 2005
Enrollment StartMay 1, 2004
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 20.8 years ago

Interventions

etanerceptdrug